Chandan Sharma
About Chandan Sharma
Chandan Sharma is an Associated Scientist at the Broad Institute of MIT and Harvard, focusing on cancer research since 2019. His work includes analyzing the effects of DHHC3 ablation on chemotherapeutic drug sensitivity and studying the role of protein acyl transferase DHHC3 in tumor growth and immune regulation.
Work at Broad Institute
Chandan Sharma has served as an Associated Scientist at the Broad Institute of MIT and Harvard since 2019. His work is primarily based at the Dana-Farber Cancer Institute in Boston. In this role, he focuses on cancer research, particularly analyzing the effects of DHHC3 ablation on the sensitivity of chemotherapeutic drugs and PARP inhibitors. His research contributes to understanding the mechanisms of tumor growth and the interaction between cancer cells and the immune system.
Education and Expertise
Chandan Sharma holds a Ph.D. in Molecular Biology and Biochemistry, which he obtained from IHBT (CSIR Institute). His educational background provides a strong foundation for his research in cancer biology and therapeutic strategies. In addition to his doctoral studies, he completed a 6-week intensive course in 2018 on 'Commercializing Technology: New Venture Creation for Life Scientists,' enhancing his knowledge of translating scientific research into practical applications.
Research Focus
Chandan Sharma's research primarily investigates the role of protein acyl transferase DHHC3 in regulating tumor growth. His studies also explore how DHHC3 influences the immune system's response to tumors. By analyzing the effects of DHHC3 ablation, he aims to uncover new insights into the sensitivity of cancer cells to various treatments, including chemotherapeutic drugs and PARP inhibitors.
Professional Development
In 2018, Chandan Sharma completed a specialized course titled 'Commercializing Technology: New Venture Creation for Life Scientists.' This program was designed to equip life scientists with the skills necessary to translate their research into viable business ventures. This experience complements his scientific expertise and enhances his ability to contribute to the commercialization of scientific innovations.